NCT00059280View on ClinicalTrials.gov

A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

September 30, 2005

Conditions
Glycogen Storage Disease Type II
Interventions
BIOLOGICAL

Myozyme

20 mg/kg qow or 40mg/kg qow

Trial Locations (8)

100

National Taiwan University Hospital, Taipei

27710

Duke University Medical Center, Durham

31096

Rambam Medical Center, Haifa

45229

Children's Hospital Medical Center, Cincinnati

84132

University of Utah Medical Center, Salt Lake City

32610-00266

University of Florida College of Medicine, Gainesville

Unknown

Pediatrique Hopital deBrousse, Lyon

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00059280 - A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease | Biotech Hunter | Biotech Hunter